|
|
Volumn 56, Issue 6, 1994, Pages 601-607
|
|
Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole
a
a
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIFUNGAL AGENT;
ITRACONAZOLE;
KETOCONAZOLE;
PLACEBO;
TERFENADINE;
TRIAZOLAM;
ADULT;
AREA UNDER THE CURVE;
ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
CROSSOVER PROCEDURE;
DOUBLE BLIND PROCEDURE;
DRUG ABSORPTION;
DRUG BLOOD LEVEL;
DRUG ELIMINATION;
DRUG HALF LIFE;
DRUG METABOLISM;
DRUG POTENTIATION;
FEMALE;
HUMAN;
HUMAN EXPERIMENT;
MALE;
NORMAL HUMAN;
ORAL DRUG ADMINISTRATION;
PHARMACODYNAMICS;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
VOLUNTEER;
ADMINISTRATION, ORAL;
ADULT;
ANALYSIS OF VARIANCE;
CYTOCHROME P-450 ENZYME SYSTEM;
DOUBLE-BLIND METHOD;
DRUG SYNERGISM;
FEMALE;
HALF-LIFE;
HUMANS;
ITRACONAZOLE;
KETOCONAZOLE;
MALE;
REFERENCE VALUES;
TRIAZOLAM;
|
|
EID: 0028568243
PISSN: 00099236
EISSN: 15326535
Source Type: Journal
DOI: 10.1038/clpt.1994.184 Document Type: Article |
|
Times cited : (272)
|
|
References (0)
|
